|
Post-treatment total cholesterol levels (mmol/L) in randomized controlled trials |
||||
| Interventions |
No. of trials [references] |
No. of participants |
Weighted mean difference (95% confidence interval) |
P value |
|
|
||||
| RYR vs. no intervention/placebo |
||||
| Zhibituo vs. no intervention |
2 [22, 23] |
112 |
-1.27 (-1.50 to -1.05) |
< 0.00001 |
| RYR supplement vs. placebo |
1 [7] |
83 |
-1.04 (-1.41 to -0.67) |
< 0.00001 |
| Xuezhikang vs. placebo |
4 [8, 24–26] |
323 |
-1.04 (-1.46 to -0.62)* |
< 0.00001 |
| Zhibituo vs. placebo |
3 [27–29] |
283 |
-0.80 (-1.03 to -0.57) |
< 0.00001 |
| RYR vs. statins |
||||
| Xuezhikang vs. simvastatin |
15 [6, 30–43] |
1455 |
0.05 (-0.27 to 0.37)* |
0.76 |
| Xuezhikang vs. pravastatin |
7 [44–50] |
594 |
- 0.20 (- 0.47 to 0.06)* |
0.14 |
| Xuezhikang vs. lovastatin |
3 [51–53] |
174 |
-0.05 (-0.27 to 0.18) |
0.69 |
| Xuezhikang vs. atorvastatin |
1 [54] |
60 |
-0.16 (-0.58 to 0.26) |
0.46 |
| Xuezhikang vs. fluvastatin |
1 [55] |
118 |
0.48 (0.24 to 0.72) |
0.0001 |
| Zhibituo vs. simvastatin |
9 [32, 56–63] |
728 |
0.11 (-0.03 to 0.25) |
0.14 |
| Zhibituo vs. provastatin |
1 [22] |
62 |
0.05 (-0.20 to 0.30) |
0.70 |
| Zhibituo vs. lovastatin |
1 [57] |
45 |
-0.11 (-0.48 to 0.26) |
0.56 |
| RYR vs. non-statin drugs |
||||
| Xuezhikang vs. inositol nicotinate |
7 [65–71] |
624 |
-0.56 (-0.81 to -0.31)* |
< 0.0001 |
| Xuezhikang vs. fenofibrate |
5 [32, 73–76] |
337 |
-0.13 (-0.46 to 0.20)* |
0.44 |
| Xuezhikang vs. gemfibrozil |
3 [77–79] |
156 |
-0.43 (-1.52 to 0.65)* |
0.43 |
| Xuezhikang vs. fish oils |
2 [80, 81] |
116 |
-0.81 (-1.11 to -0.50) |
< 0.00001 |
| Xuezhikang vs. alginic sodium diester |
1 [84] |
60 |
-1.08 (-1.38 to -0.78) |
< 0.00001 |
| Xuezhikang vs. conjugated estrogens |
1 [85] |
44 |
-0.87 (-1.20 to -0.54) |
< 0.00001 |
| Xuezhikang vs. elastase |
1 [86] |
107 |
-0.10 (-0.49 to 0.29) |
0.61 |
| Xuezhikang vs. biphenalbid |
1 [87] |
64 |
0.12 (-0.31 to 0.55) |
0.59 |
| Zhibituo vs. inositol nicotinate |
8 [88–95] |
608 |
-0.73 (-1.13 to -0.33)* |
0.0004 |
| Zhibituo vs. fish oils |
6 [97–102] |
491 |
-0.76 (-1.04 to -0.49)* |
< 0.00001 |
| Zhibituo vs. fenofibrate |
2 [32, 104] |
248 |
0.31 (0.04 to 0.59) |
0.02 |
| RYR versus RYR |
||||
| Xuezhikang vs. Zhibituo |
7 [32, 106–111] |
701 |
-0.03 (-0.25 to 0.20)* |
0.82 |
|
* Random effects model | ||||
Liu et al. Chinese Medicine 2006 1:4 doi:10.1186/1749-8546-1-4 |
||||